Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.71 |
| ▸ | PNMT | P11086 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 7/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502101 | 0.98 | CD44 (0.68) | CD44PNMTMAOBTSHRHTR2C | |
| SCHEMBL233066 | 0.93 | PNMT (0.74) | CD44PNMTMAOBTSHRHTR2C | |
| Ammonia Solution, Strong SCHEMBL20359732 | 0.91 | PNMT (0.71) | CD44PNMTMAOBTSHRHTR2C | |
| Hydrochloric Acid SCHEMBL2876610 | 0.91 | PNMT (0.71) | CD44PNMTMAOBTSHRHTR2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL18419929 | 0.89 | PNMT (0.83) | CD44PNMTMAOBHTR2CDRD2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL8723566 | 0.87 | PNMT (0.79) | CD44PNMTMAOBHTR2CDRD2 | |
| SCHEMBL23555060 | 0.84 | PNMT (0.83) | CD44PNMTMAOBHTR2CDRD2 | |
| SCHEMBL4502828 | 0.84 | HTR2C (0.76) | CD44PNMTMAOBTSHRHTR2C | |
| Pyrrolidine SCHEMBL28891967 | 0.83 | HTR2C (0.67) | CD44PNMTMAOBTSHRHTR2C | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL29360217 | 0.83 | PNMT (1.00) | CD44PNMTMAOBHTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0566069-A1 | Tachykinin receptor antagonists, isoquinolones and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | claimed |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2020228436-A1 | AROMATIC RING OR HETEROAROMATIC RING DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2020-11-19 | — | — | WO | disclosed |
| US-8252814-B2 | Agents and crystals for improving excretory potency of urinary bladder | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-28 | — | — | US | disclosed |
| US-7834182-B2 | histamine H3 receptor antagonists; metabolic disorders, sleep disorders, cardiovascular disorders, alcoholism, drug addiction, memory disorders, Alzheimer's, Parkinson's disease; 2-(4-piperidinylpiperidinyl)pyrimidine compounds such as 2-[(4-piperidin-1-yl)piperidin-1-yl]-5-(3-pyridyl)pyrimidine | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ISHIHARA YUJI | 2009-10-22 | — | — | US | disclosed |
| US-20090203710-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| EP-1891954-A2 | Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder | Takeda Pharmaceutical Company Limited (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| CN-1036458-C | Condensed heterocyclic compouds, their production and use | — | 1997-11-19 | — | — | CN | disclosed |
| EP-0560235-B1 | Condensed heterocyclic ketone derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5523305-A | ANALGESICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-06-04 | — | — | US | disclosed |
| US-5462934-A | Cholinesterase inhibitor; learning enhancement | TAKEDA CHEMICAL INDUSTRIES (JP) | 1995-10-31 | — | — | US | disclosed |
| EP-0487071-B1 | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5273974-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| EP-0566069-A1 | Tachykinin receptor antagonists, isoquinolones and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | disclosed |
| EP-0560235-A1 | Condensed heterocyclic ketone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1993-09-15 | — | — | EP | disclosed |
| EP-0487071-A1 | Condensed heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264467-A1 | Agents and crystals for improving excretory potency of urinary bladder | ACHE, BCHE, PDE7A | CD44 4772/4885PNMT 174/4885MAOB 207/4885 |
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | CD44 1294/4885PNMT 677/4885MAOB 1973/4885 |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | CD44 4372/4885PNMT 4412/4885MAOB 4347/4885 |
| US-20090203710-A1 | Novel piperidine derivative | HRH3, OPRM1, HRH4 | CD44 1231/4885PNMT 186/4885MAOB 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.